Get Multiple Myeloma Drugs Market INFOGRAPHICS 2019: The Approval Of New Drugs To Drive The Multiple Myeloma Drugs Market

The global Multiple Myeloma Drugs Market was valued at US$ XX Mn in the year 2018 and is expected to reach US$ XX Mn by the year 2026, growing at a CAGR of 11.8%.

FREMONT, United States - May 22, 2019 /MarketersMedia/ —

Industrial Analysis of Multiple Myeloma Drugs Market
Multiple myeloma is a type of blood cancer that forms in plasma cells. Plasma cells are an important part of a person’s immune system, as they make antibodies that help fight infections.

Multiple myeloma is the second most common haematological cancer. In the year 2016, there were about 130,000 cases of multiple myeloma globally. In the same year, approximately 98,000 deaths were caused by multiple myeloma. The incidence of multiple myeloma is increasing across the globe.

Get Sample INFOGRAPHICS of Multiple Myeloma Drugs Market Report:
https://www.alltheresearch.com/sample-request/107

One of the major factors to drive the growth of the multiple myeloma drugs market is the approval of new drugs for the treatment of this type of cancer. For instance, in March 2019, the National Institute for Health and Care Excellence (NICE) approved Daratumumab in combination with bortezomib and dexamethasone, for the treatment of multiple myeloma. In 2016, the U.S. FDA approved the use of daratumumab in combination with dexamethasone and lenalidomide, or dexamethasone and bortezomib, for multiple myeloma patients who have received at least one prior therapy.
In Feb 2019, Sanofi, another leading pharmaceutical company, has declared the results of Phase III studies for its anti-CD38 therapy, isatuximab. The results revealed that the drug candidate helped in extending progression-free survival in patients with multiple myeloma.

However, most of the drugs used for the treatment of multiple myeloma are nearing patent-expiry. For instance, Celgene Corporation’s Revlimid is slated to lose its patent exclusivity at the end 2019. The looming threat of patent expiry of these drugs is expected to impede the growth of the multiple myeloma drugs market.

Top Company Profiles:
The major players operating in the multiple myeloma drugs market are Bristol-Myers Squibb, Celgene Corporation, Janssen Biotech, Inc., Novartis AG (Switzerland), Genzyme Corporation, Amgen, Inc., and Millennium Pharmaceuticals, amongst others.
Most of these companies are directing their efforts towards launching combination therapies for the treatment of multiple myeloma. Celgene is one of the leading players in the multiple myeloma drugs market. It has one drug in Phase III and five drugs is Phase II clinical trials for the treatment of relapsed/refractory multiple myeloma.

INFOGRAPICS Available for this Report in Special Discounted Price, Speak to Analyst and get more information
https://www.alltheresearch.com/speak-to-analyst/107

Recent News of Multiple Myeloma Drugs Market:
• In 2016, AbbVie and Bristol-Myers Squibb announced the EU approval of Empliciti™ (elotuzumab) for the treatment of adult multiple myeloma patients who have received at least one prior therapy. Empliciti™ (elotuzumab) has been approved for use in combination with dexamethasone and lenalidomide.
• In March 2018, Celgene Corporation completed the acquisition of Juno Therapeutics, Inc. This acquisition will position Celgene as a leading cellular immunotherapy company.
• In January 2019, Bristol-Myers Squibb has announced its plan to acquire Celgene Corporation for a whopping US$ 74 billion. The deal is expected to be completed by the third quarter of 2019.

Key questions answered:
• What is the value of the overall multiple myeloma drugs market and its segments?
• What is the value of the key segments and sub-segments in the multiple myeloma drugs market?
• Which are the attractive segments and geographies for investment?
• Who are the major players in the multiple myeloma drugs market and what are the key sustainable strategies of growth adopted by these players?
• What are the key unmet needs in major multiple myeloma drugs market?

View Complete Report with TOC, Tables and Figures:
https://www.alltheresearch.com/report/107/multiple-myeloma-drugs-market

Contact Info:
Name: Rohit B.
Email: Send Email
Organization: AllTheResearch
Address: 39180 LIBERTY STREET SUITE 110, FREMONT, CA 94538, USA
Phone: 8886916870
Website: https://www.alltheresearch.com

Source URL: https://marketersmedia.com/get-multiple-myeloma-drugs-market-infographics-2019-the-approval-of-new-drugs-to-drive-the-multiple-myeloma-drugs-market/516022

Source: MarketersMedia

Release ID: 516022

Latest News

China issues travel alerts, slams US 'interference'

Jun 18, 2019

BEIJING — China issued a pair of travel warnings for the U.S. on Tuesday and slammed what it called "interference" in its internal affairs. Foreign Ministry spokesman Geng Shuang accused the U.S. of acting in bad faith in trade negotiations and said any attempts to interfere or undermine China's stability would be "doomed to fail." The volleys of criticism between the two largest economies leave them further than ever from resolving their standoff over U.S. complaints that Beijing resorts to unfair trade practices and unscrupulous methods to obtain advanced technologies. The Chinese comments followed a statement from the U.S. Trade...

China deploys Confucius in bid to boost religion controls

Jun 18, 2019

BEIJING — China has begun five-day Confucian culture immersion courses for religious leaders in the sage's hometown as part of a campaign to extend government control over faith communities through a process of sinicization. The ruling Communist Party's United Work Front Department said in a news release issued Monday that the activity was designed to ensure the primacy of traditional Chinese values above all. "To hold activities here ... is a collective tribute to excellent traditional Chinese culture and a conscious identification and integration with Chinese culture," said the release, posted on the department's website. Participants pledged to "cultivate the...

US ambassador in China makes rare visit to Tibet

Jun 18, 2019

BEIJING — The U.S. ambassador to China is making a rare visit to Tibet to meet local officials and raise concerns about restrictions on Buddhist practices and the preservation of the Himalayan region's unique culture and language. The U.S. Embassy in Beijing said Terry Branstad is visiting the Tibetan Autonomous Region and neighboring Qinghai province from Sunday through Saturday. Qinghai is a traditionally Tibetan region also known as Amdo and the birthplace of the Dalai Lama, Tibet's exiled Buddhist leader. Branstad's visit will include official meetings along with visits to religious and cultural heritage sites, schools, and "other places of...

Japan's emperor reports to Shinto gods week after succession

Jun 18, 2019

TOKYO — Japan's Emperor Naruhito performed a Shinto ritual at the palace Wednesday to report to imperial family gods the plans for the main ceremonies of his succession later this year. Naruhito ascended to the Chrysanthemum Throne on May 1, the day after his father Akihito abdicated. Naruhito, wearing a headdress and an ancient outfit dyed in the color of burnt orange, prayed at the Kashikodokoro shrine, followed by palace officials who carried the imperial regalia of a sacred sword and jewel he inherited from his father. He later prayed at two other main palace shrines. Enshrined at Kashikodokoro is...

Boeing 737 Max 8 woes crimp Asian airlines' growth plans

Jun 18, 2019

SINGAPORE — Asian airlines are cutting routes, revamping their schedules and leasing extra aircraft to fill gaps left by the grounding of Boeing 737 Max 8s after deadly crashes in Indonesia and Ethiopia killed 346 people. So far, regional carriers have managed to avoid major disruptions, but analysts expect that idling the Max 8s, a fuel-efficient update of Boeing's popular 737, will crimp growth plans in the near future. As investigations into the crashes continue, Boeing anticipates a $1 billion increase in costs related to the 737 Max, including fixing software implicated in the disasters, adding pilot training and compensating...